Overexpression of HER-2 in thick melanoma

Melanoma Research

Volumn 12, Issue 2, 2002, Pages 139-145

  Eliopoulos, P ^a   Mohammed, M Q ^a   Henry, K ^a   Retsas, S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

HER 2; Malignant melanoma; Overexpression; Prognosis

Indexed keywords

ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALKALINE PHOSPHATASE; HUMANS; IMMUNOENZYME TECHNIQUES; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SKIN NEOPLASMS; SURVIVAL RATE; UP-REGULATION;

EID: 0036246222     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200204000-00006     Document Type: Article

References (45)

1. The biology of erbB-2/neu/HER-2 and its role in cancer
2. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma
3. HER-2/neu (c-erb-B2) gene and protein in breast cancer
4. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer
5. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
6. P185neu expression in human lung adenocarcinomas predicts shortened survival
7. Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein
8. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
9. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas
10. Tissue microarrays for gene amplification surveys in many different tumor types
11. HER·2 in human cutaneous melanoma: Implications for experimental immunotherapeutics
12. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival
13. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
14. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma
15. The prognostic value of c-erbB2 in primary breast carcinomas: A study of 942 cases
16. Prognostic importance of c-erbB-2 expression in breast cancer
17. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
18. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
19. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
20. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing meta-static breast cancer that has progressed after chemotherapy for metastatic disease
21. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report
22. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
23. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
24. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
25. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
26. Taxol in malignant melanoma
27. Docetaxel (Taxotere) in advanced malignant melanoma: A phase II study of the EORTC Early Clinical Trials Group
28. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy
29. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy
30. Taxol and vinorelbine: A new active combination for disseminated malignant melanoma
31. Immunophenotypically varied cells subpopulation in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy
32. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma
33. A new American Joint Committee on Cancer staging system for cutaneous melanoma
34. Strategies for improving survival in malignant melanoma: Focus on vindesine
35. Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma
36. Prognostic index for malignant melanoma
37. Individualized prognosis for melanoma patients
38. Serum S100ß protein as a marker of disease activity in patients with malignant melanoma
39. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival
40. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
41. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
42. Overexpression of HER2/neu in solid tumours: An immunohistochemical survey
43. Chemotherapy of malignant melanoma: The European experience
44. Systemic treatment of malignant melanoma: Grade is as important as stage
45. Role of HER2 gene overexpression in breast carcinoma